Pharmaceutical

CTX-310 by CRISPR Therapeutics for Heterozygous familial hypercholesterolemia (heFH): Likelihood of Approval

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Heterozygous familial hypercholesterolemia (heFH).

Jul 6, 2024 - 04:00
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Heterozygous familial hypercholesterolemia (heFH).
Read the original article

Tags:

Previous Article

NN-6561 by Novo Nordisk for Metabolic Dysfunction-Associated Steatohepatitis (MA...

Next Article

CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoF...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Medical device lobby says it’s tired of waiting on Medicare to cover breakthrough devices

STAT+: Medical device lobby says it’s tired of waiting ...

Mar 2, 2024

FDA approves Amneal’s 505(b)(2) NDA for PEMRYDI RTU

FDA approves Amneal’s 505(b)(2) NDA for PEMRYDI RTU

Jun 15, 2023

STAT+: Biotech investors push to extend time before pills are subject to price negotiations

STAT+: Biotech investors push to extend time before pil...

Oct 18, 2023